In addition, fusion peptides can inhibit tumour growth by disrupting the RBM38-eIF4E interaction and thus upregulating the P53 levels with the goal of inhibiting tumour progression in vivo and in vitro [119]. This evidence concerns the gene RBM38 and neoplasm.